Medical genetics : impact and strategy : (genetic disease, birth defects, prenatal diagnosis) by Miles, Judith H.
STADLER SYMP. Vol. 12 (1980) University of Missouri,Columbia 33 
MEDICAL GENETICS: 
IMPACT AND STRATEGY 
(genetic disease , birth defects, prenatal diagnosis) 
JUDITH H. MILES 
Department of Child Health 
University of Missouri Health Sciences Center 
Columbia, Missouri 65212 
SUMMARY 
Genetic diseases and birth defects have a major impact 
on all levels of health care because of their enormous conse-
quences for the individual and family and because of the high 
frequency of occurrence. That over 3000 describ?d disorders 
due to either chromosome aberrations, to sing!e-gene mutations 
or to many genes acting together and with the environment · 
have been described illustrates the diversity in these dis-
eases. The concern of the medical geneticist is to establish 
an accurate etiologic diagnosis, to counsel patients and fam-
ilies concerning their risks of occurrence or recurrence and 
to devise and provide methods of preventing both the effects 
and ultimately the occurrence of genetic diseases. 
INTRODUCTION 
At the turn of the century, the rediscovery of Mendel's 
work heralded the beginnings of the science of genetics. But 
only in the last 10 years has the genetic approach to disease 
b~gun to make a significant impact on the practice of modern 
me dicine. In the United States at the turn of the century, 
approximately 150 out of every 1000 babies died during the 
newborn period. It is estimated that 5 of those 150 babies 
died from a genetic disease or a genetically related biFth de-
fect. Genetic disease constituted a small portion of infant 
mortality in the year 1900. Today, 80 years later, because of 
dramatic advances in nutrition, antisepsis, and the control of 
infectious disease, infant mortality has been reduced 90%; and 
only 15 out of every 1000 babies die. But now, almost 5 of 
those 15 babies, approximately one third, succumb to a genetic 
disease or genetically related birth defect. If we broaden 
our perspective to consider not only infant mortality statis-
tics but also the genetic conditions which lead to significant 
physical and mental disability throughout a lifetime, it be-
comes obvious that hereditary diseases constitute a major and 
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increasingly important cause of human suffering and mortality. 
An accurate figure for the overall incidence of genetic disease 
is difficult to derive since many disorders evident in the new-
born period cause death before adulthood, while many other dis-
eases such as diabetes mellitus and adult onset coronary artery 
disease, though clearly influenced by genetic determinants, do 
not become manifest until later in life. Thus, it is necessary 
to consider the causes of genetic disease in different age 
groups. Beginning in the newborn period, we find that 3-5% of 
babies have a major birth defect or genetic disease which will 
either significantly alter their lifestyle or at least require 
corrective surgery. If the same cohort of infants are re-exam-
ined at one year of age another 2-3% will be discovered to have 
some previously occult genetic disorder such as a hearing loss 
or kidney malformation. And each additional year, new genetic 
disorders will become manifest in more children so by adult-
hood 10-20 % of our original cohort can be identified to have 
a genetic disease. 
The impact of genetic disease on society is only just beginning 
to be appreciated. A review of admissions to one general pe-
diatric hospLtal revealecl tllat 26% of a-11 children were admit-
ted with clearly genetic disorders (HALL, POWERS, McILVAINE, 
EAN, 1978). Another 26 % had developmental or less well-defined 
familial disorders; only 46% of the admissions were clearly for 
non-genetic indications. Moreover, the patients with genetic 
disorders had a history of more frequent, more expensive, and 
longer hospital stays. Looking at children less than 14 years 
of age, birth defects and genetic diseases are the third most 
common cause of death. 
Genetic diseases can be classified broadly in three groups: 
chromosomal disorders, single-gene disorders, and multifac-
torial or polygenic traits. The chromosome disorders were first 
described in the late 1950's following the development of tech-
niques for preparing human chromosomes for study; in the 1970's 
with the introduction of precise banding methods, additional 
subtle and complex rearrangements were discovered. To date, 
almost one hundred well-defined chromosomal disorders have 
been described and the list grows each year (DE GROUCHY & 
T~RLEAU, 1977). Data from cytogenetic surv eys of unselected 
liveborn infants provide our best estimates of the frequency 
of chromosome abnormalities at birth. Based. on studies of 
43,558 infants, the incidence of chromosome abnormalities is 
5.6/1000 livebirths (LUBS, 1977). Of these, 2/1000 are sex-
chromosome disorders, generally an additional or deleted X or 
Y chromosome, and 1.7/1000 are autosomal aneuploidies, most 
frequently involving an extra chromosome 21, 13, or 18. Complex 
chromosome rearrangements, primarily translocations, inversions, 
and various other duplications or deficiencies, are found in 
1.9/ 1000 livebirths. Table I outlines the overall incidence 
of ch-romosomal- -synd-romes in-cl-ud-i-ng- the number- of cases expect-
ed to be born in the United States each year. Each of these 
infants and their families will require a substantial outlay 
of medical and social resources for genetic and other medical 
evaluations, for special education, for hospitalizations and 
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surgeries and in many cases for institutionalization. Down's 
Syndrome, caused by the extra chromosome 21, for example, is 
responsible for 25-30% of individuals with severe mental re-
tardation in the United States and it is estimated that more 
than $400 million dollars is spent annually in the United 
States to care for patients with this one disorder (RIMOIN, 
197 5) . 
TABLE I 
Estimated Annual Incidence of Chromosomal Abnormalities in the 
United States 
Disorder Frequency per 
10,000 births* 
Sex Chromosome Aneuploidy 
XXY karyotype 
(Klinefelter's Syndrome) 
XO karyotype 
(Turner's Syndrome) 
XXX karyotype 
XYY karyotype 
Other 
Autosomal Aneuploidy 
•rrisomy 21 (Down's Syndrome) 
Trisomy 18 (Edwards' Syndrome) 
Trisomy 13 (Patau's Syndrome) 
Other anomalies 
(balanced and unbalanced) 
*Lubs, H.A. 
*Jacobs, P.A. 
Total 
5 
0.5 
5 
5 
3 
14 
2 
1 
19 
54.5 
Expected No. 
Born in U.S. 
Each Year 
(3.5 million) 
1750 
17 5 
1750 
1750 
1050 
4900 
700 
350 
6650 
19075 
Single-gene disorders are caused by the presence of a mutant 
gene or allelic gene pair and the inheritance follows the pat-
terns described by Mendel over 100 years ago. The McKusick 
catalogue (McKUSICK, 1978) of single-gene disorders records 
2,800 specific Mendelian traits; the list has grown almost 
exponentially in the last few years as new disorders have been 
described, and older medical problems have been reinvestigated 
and their genetic bases clarified. Though most single-gene 
disorders are relatively rare, when considered individually, 
their combined incidence is high, affecting almost 2% of the 
population (TABLE II). Dominant disorders due to the presence 
of one abnormal gene generally cause structural abnormalities; 
examples of some of the more common dominant disorders include 
polycystic kidney disease, neurofibromatosis, achrondroplastic 
dwarfing syndrome, several types of hereditary deafness and 
blindness, and Huntington's Chorea. Each of these diseases 
occurs once in every 1000 to 10,000 livebirths. Other less 
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frequent dominant disorders include tuberous sclerosis, 
Marfan's Syndrome, porphyria, Alpert's kidney disease, and 
rnyotonic dystrophy. Genetic counseling for heterozygotes with 
dominant disorders provides a prospective means of preventing 
genetic disability since each person with a dominant disease 
has a 50 % risk for passing the disease on to each of his 
children. Parents carrying dominant disorders need to be 
aware of the risk. Recessive genetic disorders, each resulting 
front the presence of a mutant gene pair, occur with a combined 
frequency of 0.3%. Some of the more common recessive genetic 
dis e ases are sickle-cell anemia, cystic fibrosis, Tay-Sachs 
Disease, and phenylketonuria. Since the recessive diseases 
occur when an individual inherits the same abnormal allele 
from each parent, ma.ny of the diseases are fc ,und rnor<-, fre-
quently in specific ethnic groups or nationa 2.. i ties wrc dre 
likely to share a common gene tic heritage. Therefore, sickle-
cell anemia is more common in the black population; cystic 
fibrosis in the European caucasians; Tay-Sachs Disease in 
Ashkenazi Jews, and beta thalassemia iri ·, Mediterraneans. Most 
recessive disorders however are wide-spread throughout the 
world regardless of ethnic heritage. Some of the more common 
examples are alpha-1-antitrypsin deficiency, Friedreich's 
ataxia,~ )21l~nylketonuri9 , galactosemia ,_____m_aple-syrup urine 
disease, albinism, Wilson's Disease, ithe amino acidopathies, 
glycogen storage diseases, and the mudopolysaccharidoses. For 
each recessive disease, once a child is born with the disor-
der or when both parents have been demonstrated to be car-
riers, the risk for each subsequent chi,ld is 25%. 
TABLE II 
I I 
Estimated Burde n of Mendelian and Multifactorial Genetic 
Disease in the United States 
Mode of 
Inheritance 
Autosomal dominant 
Autosomal recessive 
X-linked 
Multifactorial 
Total 
*Lubs, H. A. 
Frequency per 
10,000 births* 
60 
30 
10 
120 
220 
Expected No. Born 
Each Year In 
United States 
( 3 .5 millon births) 
21,000 
10,500 
3,500 
42,000 
77,000 
Genes mapped to the X chromosome are considered separately 
since the risk of occurrence <liffers for females with two 
X chromosomes and males with a single X and a Y chromosome. 
Hemophilia, Duchenne muscular dystrophy, glucose-6-phosphate 
dehydrogenase deficiency, and color blindness are well-known 
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examples of X-linked recessive disorders which affect males 
more than females. Another 200 clinically significant X-
linked traits have been described including retinitis pig-
mentosa, agammaglobulinemia, ocular albinism, and Lesch-Nyhan 
Disease. Recently, there has been an increased interest in 
mental retardation caused by X-linked recessive genes. We 
know that in institutions there is a 50% excess in retarded 
males over females; many of these disorders may be due to 
either single or multiple X-linked genes. It is estimated 
that as many as 35% of all persons with IQ's of less than 70 
have some form of X-linked mental retardation (LEHRKE,1974) . 
The recent discovery of cytologically demonstrable .. fragile 
sites on the X chromosome of some men with X-linked mental 
retardation promises to be a valuable tool for the geneti-
cist who is trying to coordinate clinical genetic and cyto-
genetic findings. · 
The largest number of medically significant genetic disorders 
are not due to single genes or gene pairs. •Ratl,er they are 
caused by multiple genes adversely acting together and with 
the environment. Cleft lip and palate, spina bifida (open 
spine), anencephaly (open brain), club feet, many congenital 
heart diseases, hydrocephalus, congenital hip dislocations, 
congenital scoliosis, many urinary tract anomalies, Hirsch-
prungs Disease, and pyloric stenosis are all examples of birth 
defects or disorders which follow this inheritance pattern. 
These disorders each occur approximately once in every 1000 
livebirths. Their combined incidence approaches 1% of the 
babies born in the United States. Many other common diseases 
which usually occur later in life including essential hyper-
tension, athrosclerotic heart disease, atopic allergic cond-
itions, schizophr,enia, and some types of diabetes are also 
due to multifactorial causes. They occur in at least 10% of 
the population. 
By tabulating incidence figures, we can only just begin to com-
prehend the real impact of genetic disease on society. Chil-
ren born with serious birth defects usually face a shortened 
life span marred by frequent hospitalizations and surgeries. 
In addition, the financial burden of providing hospital, med-
ical, and institutional care is enormous. For example, the 
average cost to provide care for one child with Down's Syndrome 
is $10,000 per year (RIMOIN, 1975). Since Down's Syndrome oc-
cur,s in one of every 600 babies born in the United States, it 
is not difficult to recognize that the estimated annual expend-
iture of over $400 million for children with Down's Syndrome 
is conservative. Realistically, this figure must be multi-
plied many times to estimate the costs incurred for all chil-
dren born with other birth defects O+ genetic diseases. And 
since individual families rarely have the financial resources 
to provide these services, the costs are assumed by society 
through numerous federal, state, and municipal governmental 
agencies. 
But perhaps of even greater significance is the devastating 
impact of genetic disease on families. Following the birth 
of an affected child, parents suffer not only a profound sense 
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of sadness and loss but also experience undeserved and irra-
tional feelings of guilt and shame. Couples feel a sense of 
failure and loss of self-esteem which leads to an inevitable 
breakdown in communications and mutual support. Family dis-
ruption and divorce rates more than double following the birth 
of a damaged child. Collapse of the family is catastrophic 
for both the affected child and for society. The child is 
more apt to be place d in a state school or foster home and 
society loses the commitment of the parents and family, who 
are our most powerful advocates in the crusade for continued 
progress in the fight to control and prevent genetic diseases 
and birth defects. 
STRATEGY: PREVENTION 
Genetic diseases cannot yet Le cured. DNA cannot be ma-
nipulated to repair the deleterious genes which we all contin-
ue to pass from generation to generation. And so, without an 
available method to cure defects in the genome but faced with 
the increasing medical, financial and personal burdens of ge-
netic disease, medical geneticists have focused their atten-
tion on the aspects of prevention. The key to our understand-
ing~ of geneti~s has always been predictability. Utilizing our 
ability to accurately anticipate the occurrence of a disease, 
strategies of prevention have been and are continuing to be 
developed. Prevention can take many forms. Because most ge-
netic disorders can not be recognized until after birth, ge-
neticists emphasize the preventive potential of therapy, which 
is essential to prevent the deleterious consequences of many 
diseases. For example, surgical cleft lip and palate repair 
in the first few months of life can often completely circum-
vent the destructive effects that an unrepaired cleft would 
have on speech and personality de ve lopment. Similarly, club 
feet and dislocated hips can be repaired before the time of 
walking so children won't be impeded in their acquisition of 
normal motor development. Drug therapy for seizures and insu-
lin for diabetes prevent the complications of those disorders. 
In all these cases where the basic genetic defect is not yet 
understood, therapy to correct the existing problems remains 
a powerful though generally less than optimal method of pre-
vention. 
For a growing number of inborn errors of metabolism, our cur-
rent understanding of the biochemical me chanisms allows elegant 
specific genetic therapy. For example, the infant with the 
autosomal recessive disorder galactosemia appears normal at 
birth. When milk feedings are introduced, however, vomiting 
and listlessness develop, the liver enlarges and jaundice 
develops. Approximately two thirds of the babies die before 
a correct diagnosis is made and if they survive and remain 
untreated their life is marred by severe mental retardation, 
cataracts and liver damage. However, when the diagnosis of 
galactosemia is recognized in the first days of life , the 
diet can be changed and a soy formula substituted for the milk 
formulas which contain galactose. This simple prescription 
will prevent all of the harmful consequences of galactosemia. 
The development of preventive therapy for galactosemia was 
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a major breakthrough in the treatment of genetic diseases and 
reflects our increasing understanding of the biochemical bases 
of the inborn errors of metabolism. U:qf_ortunately, for many 
other genetic diseases, therapy will be too late and babies 
will be seriously damaged if we wait for a diagnosis to be 
made on the basis of classical medical presenting signs and 
symptoms. To circumvent this dilemma, medical geneticists 
have endeavored to find ways of screening for damaging condi-
tions before they become clinically obvious. An increasing 
number of examples of the successful application of this ap-
proach occur in the newborn nursery (HOLTZMAN, 1S78). Infants 
with these diseases are protected in utero by the mother's 
intact metabolic machinery. For example, the fetus unable 
to break down phenylalanine because of a deficiency of phenyl-
alanine hydroxylase is not damaged as long as his nutritional 
and catabolic needs are being supplied by the mother. It is 
after birth that phenylalanine and its by-products begin to 
accumulate and cause insidious and irreversible damage to the 
nervous system. By testing all newborns in the first few days 
of life for increased levels of phenylalanine, but before the 
breakdown products build up, the few infants who are affected 
can be identified and appropriately treated before damage 
occurs. Screening for phenylketonuria (PKU) is now mandated 
by state law in all fifty of the United States; though the 
incidence is only 6-7 per hundred thousand infants screened, 
those who are identified are saved from mental retardation 
and its consequences. Similarly, maple-syrup urine disease 
caused by a branched-chain of ketoacid decarboxylase deficien-
cy, galactosemia caused by a galactose-1-phosphate uridyl 
transferase deficiency, and congenital hypothyroidism can all 
be chemically detected in the newborn period before symptoms 
occur. Hypothyroid screening is now done in_ more than half 
the states and pilot projects designed to assess the efficiency 
of screening for numerous other disorders are underway. These 
studies are critical since the benefits of newborn screening 
must be precisely delineated for each specific disease before 
mass screening is initiated. Experience has taught us that 
the ability to test for genetic disease does not assure success 
of a screening program. Other considerations including the 
ability to reach the target population, methods of dealing 
with the false-negative and false-positive screening results, 
ways of assuring adequate followup and means of reducing the 
high cost of screening are problems which must be worked out 
before effective mass screening can be introduced for any of 
the genetic diseases. 
For hundreds of other genetic diseases, damage is already 
present at birth and methods of treatment are not available 
even after the cliagnosis is made. The availability of suc-
cessful modes of treatment determines in large measure the 
burden of a disorder for the child and family; for most genetic 
diseases, no specific therapy is available. Children with 
Tay-Sachs Disease for example, always die in the first 3-5 
years of life despite all the efforts of modern medicine. Their 
life is marked by a steady downhill course of neurological 
degeneration causing deafness, blindness, and seizures.Examples 
of other serious untreatable genetic diseases include Menke's 
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kinky-hair syndrome caused by an as yet poorly understood 
disorder in copper metabolism and Hurler's mucopolysaccha-
ridosis which results in the inability to break down complex 
sugars. Children born with theie disorders cannot be success-
fully treated. And the survival of babies born with severe 
malformations such as spina bifida and hydrocephalus general-
ly depends on a series of major surgeries, complex medical 
care and frequent hospitalizations. Understandably, where 
morbidity and mortality is high, parents wish to prevent the 
birth of a second affected child. The query from parents, "Will 
it happen again?", generally initiates a genetic evaluation. 
Genetic counseling is the popular synonym for the medical 
genetic evaluation. The process however i~ not limited to 
providing a risk of recurrence for the family. A specific 
diagnosis must be available before adequate risks can be esti-
mated. Often the family and medical history provide the 
geneticist information on the etiology of the problems. For 
example, the family history may reveal other similarly or 
less affected relatives or could point to a specific mode of 
inheritance in that family. In some cases, an environmental 
factor such as maternal rubella, alcoholism or drugs taken in 
pregnancy is fnund to be the responsible- age~t-.~ RFequen~~~, 
the clinical evaluation requires the use of laboratory or 
radiographic tests to confirm the suspected diagnosis. The 
value of the diagnosis cannot be underestimated for it allows 
the geneticist to draw on the experience of other physicians 
and families in order to prognosticate both medically and 
genetically what the patient and family can expect in the 
future. Host patients affected wi'th an unusual genetic syn-
drome or disease, whether due to a chromosome abnormality, a 
biochemical error of metabolism, or a physical ' malformation, 
will require the consultation of a medical geneticist to con-
firm the diagnosis and to establish the most likely mode of 
inheritance. If the risk of recurrence is high, and if the 
prognosis for the disorder is poor, couples must decide whether 
they wish to have other children. Contraception, sterilization, 
and adoption are possible options. When the father carries 
the detrimental gene or in autosomal recessive conditions, 
artifical insemination may be an option for some families. 
In the last 10 years, prenatal diagnosis has provided many 
families with a new and positive alternative when the risks 
of recurrence were high and the prognosis was poor. Trans-
abdominal amniocentesis at 16 weeks into the pregnancy has 
proved to be a safe and accurate p'rocedure which allows the 
geneticist to sample fetal cells sloughed into the amniotic 
fluid and to utilize these cells and the fluid itself to diag-
nose specific genetic diseases (NICHD, 1976). In addition, 
ultrasonic techniques allow the fetus to be safely visualized 
and measured in utero providing both the geneticist and the 
obstetrician a means of detecting certain morphologic abnor-
mali ties- early~ i-n- ]c>-regnaney-. ~ Present-ly, a-1-1 chromusome- dis-
orders, plus more than 70 biochemical disorders or structural 
birth defects can be diagnosed in utero. The list of defects 
which can be detected in the fetus continues to grow as new 
biochemical tests become available and as cytogenetic tests 
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are improved (MILES & KABACK, 1978). 
Prenatal diagnosis adds a new dimension to genetic counseling 
by providing couples at risk for certain serious genetic 
disorders with an alternative and in many instances a positive 
course of action. Because the risk of an abnormality rarely 
exceeds 25%, as in autosomal recessive conditions, couples 
have an excellent chance through prenatal diagnosis of having 
unaffected offspring. This implies, of course, that such 
families would elect to monitor their pregnancies by amnio-
centesis and electively terminate those in which an affected 
fetus is identified. 
Genetic counseling has been described ·as a process of communi-
cation during which the physician or other trained counselor 
helps the family to understand better the genetic and medical 
aspects of an inherited disease. The goals of genetic coun-
seling are to provide families with complete and appropriate 
information, to aid them in making decisions that are in the 
best interestes of their family, and to help them make the 
best possible adjustment to those decisions. 
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